Navigation Links
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Date:9/10/2007

ete

resolution of lung metastases by CT/PET with significant improvement in

dypsnea (shortness of breath);

-- 1 patient (11 prior regimens, 5 with trastuzumab, 2 with lapatinib)

showed 10% reduction in tumor mass with change consistent with tumor

necrosis and a decrease in 2 tumor markers (64% CEA, 63% CA27.29);

-- 1 patient (5 prior regimens) showed a partial response after 2 cycles,

confirmed after 4 cycles, with 52% decrease hepatic lesions);

-- 5 patients had extended stable disease (4, 6+, 6+, 8 and 10 months).

Of the 3 patients with ovarian cancer,

-- 1 patient (13 prior regimens) who was on study for more than 19 months

with evaluable disease had a near complete resolution of ascites and

left pleural effusion at the end of cycle 2, and an 83%

decrease in CA125.

Toxicities were mainly Grade 1 and 2 (diarrhea, fatigue, headache, arthralgia, nausea). One patient with multiple prior trastuzumab and doxorubicin containing regimens experienced a dose-limiting toxicity of shortness of breath and left ventricular ejection fraction reduction at 100 mg/m2. Two patients treated at 80 mg/m2 experienced reversible Grade 3 ocular keratitis; following a treatment holiday both patients continued therapy with reduced doses (one patient remains on study). Kosan plans to continue to enroll patients at the 80 mg/m2 for further safety and efficacy evaluation.

Expanded Phase 1 Trial Includes Paclitaxel

Kosan has expanded the Phase 1 trial to add weekly dosing with paclitaxel (Taxol (R)). In this triplet combination regimen, patients will continue to receive trastuzumab at full dose on a continuous weekly schedule. Alvespimycin will be dosed weekly for 3 weeks out of 4, and paclitaxel will be given on the same schedule.

Alvespimycin Development Plan

In the fourth quarter of 2007, Kosan plans to initiate a Phase 2 trial of alvespimycin as monotherapy
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
6. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
7. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
8. ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)...   National Community Pharmacists Association (NCPA) CEO ... issued the following statement today regarding a survey ... "preferred pharmacy" drug plans , which often exclude ... advertised co-payments: (Logo:  http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... MedPAC , 16 U.S. Senators and more ...
(Date:5/20/2013)... 2013 /PRNewswire-iReach/ -- Today at American Society for ... Ginocchio discussed Specific Technologies blood culture ... of microorganisms producing bloodstream infection. Dr. Ginocchio is ... Division of Infectious Disease Diagnostics at North Shore-LIJ ... health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ) ...
(Date:5/20/2013)...  Hill-Rom Holdings, Inc. (NYSE: HRC ) ... the 38 th Annual Deutsche Bank Health Care ... 30, 2013, at 1:30 p.m. EDT. (Logo: ... to listen to the live discussion via the internet ... at http://www.media-server.com/m/p/f7bj3q84 . A recorded replay of the ...
Breaking Medicine Technology:Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3
... ANN ARBOR, Mich., Feb. 6, 2012  Adeona Pharmaceuticals, Inc. ... synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious ... Director appointments to strengthen and expand the Company,s leadership, ... of the Adeona Board of Directors since March 2010 ...
... Feb. 6, 2012  EntreMed, Inc. (Nasdaq: ENMD ), ... cancer, announced today that Wei-Wu He, Ph.D has joined the ... Ph.D has joined as a member of the Board of ... Dr. Wei-Wu He is currently the CEO and Chairman of ...
Cached Medicine Technology:Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 2Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 3Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 4Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 5Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 2Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 3Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 4
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... PHILADELPHIA The surgical management of non-small cell lung ... the race of the patient, according to a new ... I and Stage II NSCLC is surgery," said researcher ... in Omaha, Nebraska. "In our study of more than ... the years 2000 and 2010, we found statistically significant ...
(Date:5/21/2013)... Clinical measurement of physical activity appears to be ... with chronic obstructive pulmonary disease (COPD) will end ... conducted by researchers in Connecticut. The study also ... of inactivity with an increased incidence of hospitalizations ... the study will be presented at the ATS ...
(Date:5/21/2013)... PHILADELPHIA─Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a ... breakdown and protects the lung,s elasticity, is effective ... with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic ... the 2013 American Thoracic Society International Conference. , ... the loss of lung tissue as measured by ...
(Date:5/21/2013)... 2013 Barbara Michels, author of “ ... over 50 years of experience in the world of ... both her mom and dad to Alzheimer’s disease ... volunteer with the New Mexico Chapter of the Alzheimer’s ... and insight into the many challenges caregivers experience. Through ...
Breaking Medicine News(10 mins):Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Exercise levels may predict hospitalizations in COPD population 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 3Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 2Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 3Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 4
... It,s the time of year when more,than 1.5 million ... up the sun and drink large quantities of alcohol. Students ... as much as,those who stay home with parents or relatives, ... Journal of Studies on Alcohol and Drugs., Instead of ...
... to request more aggressive therapy, study finds , , TUESDAY, ... can help predict the risk of cancer recurrence in ... therapy, a new U.S. study says. , Researchers from ... review of MRI images taken before 80 prostate cancer ...
... Professional Marketing Inc. also assessed civil penalty of,$512,000, ... Inc. (APMI), a medical staffing company based in ... have been charged by the U.S.,Department of Labor ... that authorize employers to bring non-immigrant workers,into the ...
... Cancer Center will open a Phase I pancreatic ... leading researchers from Israel, marking the first time ... counterparts in Israel. , The study is ... Bi-National Industrial Research and Development Foundation (BIRDF). Leaders ...
... Top 1 Million for First Time, ARLINGTON ... of cosmetic plastic surgery procedures were performed,on ethnic ... year, including,Hispanics, African Americans and Asian Americans, according ... Plastic Surgeons (ASPS)., Since 2006, cosmetic plastic ...
... Tiered Copayments, Generics, and the,Mail-Service Pharmacy Option to ... new survey of,employers that finds the utilization of ... cost of prescription drug benefits highlights the,value of ... savings,and access for payors and consumers, the Pharmaceutical ...
Cached Medicine News:Health News:It's Spring Break: How Much Does Heavy Drinking Affect Your Body? 2Health News:MRI Can Be Predictor of Post-Treatment Prostate Cancer Spread 2Health News:New York City Staffing Company Charged With Violating H-1B Program Following U.S. Labor Department Finding Almost $3 Million in Back Wages Due 156 Workers 2Health News:VCU Massey Cancer Center to partner with Israeli biotech firm 2Health News:VCU Massey Cancer Center to partner with Israeli biotech firm 3Health News:Cosmetic Plastic Surgery Procedures for Ethnic Patients up 13 Percent in 2007 2Health News:Employers: Proven PBM Tools Slowing Cost of Prescription Drug Benefits 2
Long-Sleeve Bolero for targeted compression in the upper arms, upper back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Velcro® closure, uniform contour compression, available as 9" and 12" bands for abdominal support, 9" can be used as a breast wrap....
Sub Pectoral Breast Augmentation Wrap...
CDIs Ultra-Comfort Bra™ is designed with special single needle stitching that places the cup seams away from critical surgical sites....
Medicine Products: